2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 906

Defining the Gut Microbiome in Patients with ANCA-Associated Vasculitis
Abstract Number: 674

Defining the Therapeutic Target in Psoriatic Arthritis: MDA Versus Dapsa
Abstract Number: 2703

Delay in Initiation of Therapy Predicts Worse Outcomes in Scleroderma Renal Crisis
Abstract Number: 911

Demographic and Clinical Characteristics Reflect Differences in Osteoarthritis Phenotypes of the Lumbar Spine: The Johnston County Osteoarthritis Project
Abstract Number: 796

Demographic and Clinical Features of Systemic Sclerosis Patients with Anti-U1RNP Antibodies: A European Scleroderma Trials and Research (EUSTAR) Analysis
Abstract Number: 31

Dendritic Cell-Specific Transmembrane Protein (DC-STAMP) Regulates Inflammation and Joint Damage in the TNF-Tg Mouse Model
Abstract Number: 90

Deoxyribonuclease 1-like-3 Digests Self-DNA from Dead Cells and Prevents Autoimmunity
Abstract Number: 1598

Depression and Anxiety Reduce Probability of Achieving a State of Minimal Disease Activity in Patients with Psoriatic Arthritis
Abstract Number: 1389

Depression and the Patient Reported Outcomes Measurement Information System in Systemic Lupus Erythematosus
Abstract Number: 1660

Depression Has a Greater Impact on Psoriatic Arthritis Than Rheumatoid Arthritis
Abstract Number: 1510

Depression Is a Major Driver of Functional Capacity in Patients with Rheumatoid Arthritis Regardless of Disease Activity
Abstract Number: 292

Derivation of a National Rheumatoid Arthritis Cohort in the Veterans Health Administration and Validation with the Veterans Affairs Rheumatoid Arthritis Registry
Abstract Number: 938

Dermal Lymphatic Dysfunction and Photosensitivity in the MRL/Lpr Lupus Model
Abstract Number: 876

Dermatomyositis Skin Shares Type I Interferon Overlap with Cutaneous Lupus but Displays Many Unique Expression Changes That May Serve As Biomarkers for Skin Disease
Abstract Number: 2590

Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Patients with Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].